In a man with type 1 diabetes and tetraplegia, daily subcutaneous insulin decreased to 150 U after pramlintide treatment.
In plain wordsIn a man with type 1 diabetes and tetraplegia, daily injected insulin decreased to 150 U after pramlintide treatment.
- Peptide
- Pramlintide (Symlin)
- Outcome
- DecreaseDaily subcutaneous insulin requirement
- Study
n = 1
- Comparator
- Pre-pramlintide total daily subcutaneous insulin of 600 U
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · 22 monthsAs given in this study (human).
Measurements
- Total daily subcutaneous insulin dose
- 150 U
- 22 months after onset of pramlintide
- Total daily subcutaneous insulin dose
- 1.3 U/kg
- 22 months after onset of pramlintide
- Total daily subcutaneous insulin dose
- 600 U
- Before pramlintide
- Total daily subcutaneous insulin dose
- 4 U/kg
- Before pramlintide
Source sentences
Twenty-two months after the onset of pramlintide treatment his total daily dose of subcutaneous insulin was decreased to 150 U (1.3 U/kg).
4 context sentences(design, population, supporting numbers)
He remained in rehabilitation for 18 months and returned home with a total daily dose of subcutaneous insulin of 600 U (4 U/kg); a 500 U increase over his prespinal cord injury requirements.
The patient is a 43-year-old male who was diagnosed with type 1 diabetes mellitus at age 18.
The patient became ventilator-dependent and tetraplegic.
The patient was started on pramlintide.